Coronary Artery Disease Market by Type (Diagnostics, Treatment), End-User (Ambulatory Surgery Centers, Diagnostic Centers, Hospitals & Clinics) - Global Forecast 2024-2030

Coronary Artery Disease Market by Type (Diagnostics, Treatment), End-User (Ambulatory Surgery Centers, Diagnostic Centers, Hospitals & Clinics) - Global Forecast 2024-2030

The Coronary Artery Disease Market size was estimated at USD 11.88 billion in 2023 and expected to reach USD 12.53 billion in 2024, at a CAGR 5.68% to reach USD 17.49 billion by 2030.

Coronary artery disease (CAD) is a medical condition characterized by the blockage or narrowing of coronary arteries, which are major blood vessels supplying oxygen and nutrients to the heart. This disease is primarily caused by the buildup of plaque, a combination of fat, cholesterol, and other substances in the artery walls. This buildup restricts the blood flow to the heart, leading to symptoms, including chest pain and, in severe cases, heart attacks. The major factors that contribute to the expansion of CAD include an aging population and increased prevalence of lifestyle-related risks such as obesity, diabetes, poor diet, physical inactivity, and smoking. However, the high costs of advanced therapeutic devices and product recall issues associated with CAD devices hinder market growth. Despite these issues, growing initiatives in personalized medicine and new therapeutic approaches are expected to provide tailored treatment options, reducing the overall burden of the disease.

Regional Insights

The Americas, particularly the United States, shows strong market growth owing to advanced healthcare infrastructure and a high prevalence of CAD, raising the need for advanced treatments. Additionally, significant investment in healthcare and high awareness about coronary artery disease drives the market in the region. Europe exhibits a robust healthcare system and strong regulatory frameworks that aid in the effective management of CAD. In the Middle East and Africa, the market in this region is growing, driven by increasing healthcare development and rising awareness of CAD. Asia-Pacific is experiencing rapid growth in the CAD market, propelled by increasing healthcare expenditure and growing awareness of cardiovascular diseases in populous countries, including China and India. Further, improvements in healthcare infrastructure and the rising middle class are contributing to a stronger focus on heart disease treatments and an expanding market.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Coronary Artery Disease Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

Rising incidences of coronary artery disease due to aging populations
Expansion of healthcare infrastructure with increasing investments in healthcare infrastructure

Market Restraints

High cost of advanced therapeutic devices and limited commercialization of advanced technologies

Market Opportunities

Advancements and improvements in CAD management products
Continuous expansion of minimally invasive procedures and surgery centers

Market Challenges

Problems associated with product recalls due to safety concerns

Market Segmentation Analysis

Type: Growing need for surgeries to manage CAD effectively and improve the quality of life
End-User: Higher preferences for hospitals and clinics that offer integrated CAD care

Market Disruption Analysis

Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Coronary Artery Disease Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Coronary Artery Disease Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Abbott Introduces Enhanced Xience Sierra Stent System for Improved Cardiac Care

Abbott Laboratories unveiled the Xience Sierra coronary stent system, which is designed to assist patients suffering from coronary artery disease. The newly launched stent system represents an advancement in the treatment of heart ailments by offering greater flexibility and a wider range of sizes compared to previous models. This innovation aims to cater to complex and challenging anatomies, thereby potentially increasing the success rates of angioplasty procedures.

Innovative Startup Revolutionizes Coronary Artery Disease Detection with AI Technology

Genexia has developed a cutting-edge artificial intelligence (AI) system aimed at improving the diagnosis of coronary artery disease (CAD). This AI tool integrates seamlessly with existing medical imaging technologies to analyze cardiovascular images with heightened accuracy and speed, thereby facilitating earlier and more precise diagnoses of CAD. The technology promises to enhance patient outcomes by enabling timely medical intervention and stands to significantly reduce the workload of cardiologists by automating complex diagnostic processes. Th

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Coronary Artery Disease Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Coronary Artery Disease Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, B. Braun SE, Becton, Dickinson and Company, Biotronik SE & Co. KG, Boston Scientific Corporation, Canon Medical Systems Corporation, Edwards Lifesciences, FUJIFILM Holdings Corporation, GE HealthCare Technologies, Inc., Genesee Biomedical Inc., Getinge AB, Hitachi, Ltd., Koninklijke Philips N.V., Medtronic PLC, Merck KGaA, MicroPort Scientific Corporation, Siemens Healthineer AG, Stryker Corporation, Teleflex Incorporated, and Terumo Corporation.

Market Segmentation & Coverage

This research report categorizes the Coronary Artery Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
Diagnostics
Cardiac Catheterization & Angiogram
Echocardiogram
Electrocardiogram
Exercise Stress Test
Heart CT Scan
Nuclear Stress Test
Treatment
Medications
Angiotensin-converting Enzyme Inhibitors & Angiotensin II Receptor Blockers Nitroglycerin
Aspirin
Beta-blockers
Calcium Channel Blockers
Cholesterol Drugs
Ranolazine
Surgeries
Coronary Angioplasty & Stent Placement
Coronary Artery Bypass Graft Surgery
End-User
Ambulatory Surgery Centers
Diagnostic Centers
Hospitals & Clinics
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year